Safety of the Study Drug REGN20934 in Adults With Overweight or Obesity
Tests how safe REGN20934 is in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Key facts
- Where
- Glendale, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07594093, who can take part
Where in United States
- Parexel InternationalGlendale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT07594093
- Record updated
- 25 September 2026
- Original description
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.Read full original descriptionShow less
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
The study is looking at:
* What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Inclusion: Has a Body Mass Index (BMI) 25 to 35 kg/m\^2; Females must be of non-childbearing potential.
Exclusion: History of type 1 or type 2 diabetes; History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol; Note: Other protocol defined inclusion/exclusion criteria apply; A self-reported change of body weight >5 kg within approximately 90 days of visit 2.